Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause : a clinical trial
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/109962 |
Resumo: | Background: Much attention has been drawn to the deleterious effects of adding progestins to estrogen as hormone therapy (HT) in postmenopausal women. Some widely prescribed progestins have been shown to partially oppose the beneficial effects of estrogens on surrogate markers of cardiovascular disease (CVD) risk. Progestins with higher androgenic activity may interfere with lipid profile and glucose tolerance, and could affect mechanisms of estrogen-induced C-reactive protein (CRP) stimulation. Recent data have shown that norpregnane derivatives, but not micronized progesterone, increase the risk of venous thromboembolism among transdermal estrogens users. The aim of the present study was to assess the effects of combining micronized progesterone with non-oral estrogen therapy on lipid profile and cardiovascular risk factors in a sample of early postmenopausal women. Methods: Clinical trial including 40 women receiving intranasal 17β estradiol 3 mg/day for two months and 46 women receiving percutaneous 17β estradiol gel 1.5 mg/day for three months (E2). Both groups received an additional 200 mg/day of micronized progesterone by vaginal route 14 days/month (E2+P). Outcome measures included body weight, waist circumference, body mass index (BMI), lipid profile and ultra-sensitive C-reactive protein (usCRP) at baseline and during the E2 or E2+P portions of treatment. Results: Mean age was 51±3 years. Mean time since menopause was 22.2±10 months. Most participants were overweight; HT did not change BMI. E2 and E2+P did not affect waist circumference and weight. Menopausal symptoms improved after HT. The effects of intranasal and percutaneous estradiol were similar, regardless of the addition of progesterone. Similarly, for the overall group of 86 women, micronized progesterone did not alter the response to E2. Blood pressure, glucose, insulin, HDL-c, triglycerides, and usCRP remained constant with or without micronized progesterone. Total cholesterol decreased after E2, and progesterone maintained this reduction. LDL-c levels were similar at baseline and with E2, and lower during E2+P in relation to baseline. Conclusions: Cyclic, short term exposure to vaginal micronized progesterone did not alter the metabolic and cardiovascular effects of non-oral E2 in early, apparently healthy, postmenopausal women. Trial registration: ClinicalTrials.gov NCT01432028. |
id |
UFRGS-2_98b0b385640a96dc6ff24b0518f2e861 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/109962 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Casanova, Gislaine KrolowSpritzer, Poli Mara2015-02-11T02:18:07Z20121476-511Xhttp://hdl.handle.net/10183/109962000867380Background: Much attention has been drawn to the deleterious effects of adding progestins to estrogen as hormone therapy (HT) in postmenopausal women. Some widely prescribed progestins have been shown to partially oppose the beneficial effects of estrogens on surrogate markers of cardiovascular disease (CVD) risk. Progestins with higher androgenic activity may interfere with lipid profile and glucose tolerance, and could affect mechanisms of estrogen-induced C-reactive protein (CRP) stimulation. Recent data have shown that norpregnane derivatives, but not micronized progesterone, increase the risk of venous thromboembolism among transdermal estrogens users. The aim of the present study was to assess the effects of combining micronized progesterone with non-oral estrogen therapy on lipid profile and cardiovascular risk factors in a sample of early postmenopausal women. Methods: Clinical trial including 40 women receiving intranasal 17β estradiol 3 mg/day for two months and 46 women receiving percutaneous 17β estradiol gel 1.5 mg/day for three months (E2). Both groups received an additional 200 mg/day of micronized progesterone by vaginal route 14 days/month (E2+P). Outcome measures included body weight, waist circumference, body mass index (BMI), lipid profile and ultra-sensitive C-reactive protein (usCRP) at baseline and during the E2 or E2+P portions of treatment. Results: Mean age was 51±3 years. Mean time since menopause was 22.2±10 months. Most participants were overweight; HT did not change BMI. E2 and E2+P did not affect waist circumference and weight. Menopausal symptoms improved after HT. The effects of intranasal and percutaneous estradiol were similar, regardless of the addition of progesterone. Similarly, for the overall group of 86 women, micronized progesterone did not alter the response to E2. Blood pressure, glucose, insulin, HDL-c, triglycerides, and usCRP remained constant with or without micronized progesterone. Total cholesterol decreased after E2, and progesterone maintained this reduction. LDL-c levels were similar at baseline and with E2, and lower during E2+P in relation to baseline. Conclusions: Cyclic, short term exposure to vaginal micronized progesterone did not alter the metabolic and cardiovascular effects of non-oral E2 in early, apparently healthy, postmenopausal women. Trial registration: ClinicalTrials.gov NCT01432028.application/pdfengLipids in health and disease. London. Vol. 11 (2012), 7p.LipídeosPós-menopausaProgesteronaEstrogêniosTerapia de reposição hormonalLipid profileEarly postmenopauseMicronized progesteroneNon-oral estrogenHormone therapyEffects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause : a clinical trialEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSORIGINAL000867380.pdf000867380.pdfTexto completo (inglês)application/pdf251739http://www.lume.ufrgs.br/bitstream/10183/109962/1/000867380.pdf8661a524680ced1e5b27ad02bc8a471aMD51TEXT000867380.pdf.txt000867380.pdf.txtExtracted Texttext/plain31200http://www.lume.ufrgs.br/bitstream/10183/109962/2/000867380.pdf.txt7daa1b76766cb532f6c2b51fb18d7083MD52THUMBNAIL000867380.pdf.jpg000867380.pdf.jpgGenerated Thumbnailimage/jpeg1841http://www.lume.ufrgs.br/bitstream/10183/109962/3/000867380.pdf.jpg8c38cffd5aba14c9119f1082d9ca9f9cMD5310183/1099622019-01-11 04:08:40.849705oai:www.lume.ufrgs.br:10183/109962Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2019-01-11T06:08:40Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause : a clinical trial |
title |
Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause : a clinical trial |
spellingShingle |
Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause : a clinical trial Casanova, Gislaine Krolow Lipídeos Pós-menopausa Progesterona Estrogênios Terapia de reposição hormonal Lipid profile Early postmenopause Micronized progesterone Non-oral estrogen Hormone therapy |
title_short |
Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause : a clinical trial |
title_full |
Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause : a clinical trial |
title_fullStr |
Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause : a clinical trial |
title_full_unstemmed |
Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause : a clinical trial |
title_sort |
Effects of micronized progesterone added to non-oral estradiol on lipids and cardiovascular risk factors in early postmenopause : a clinical trial |
author |
Casanova, Gislaine Krolow |
author_facet |
Casanova, Gislaine Krolow Spritzer, Poli Mara |
author_role |
author |
author2 |
Spritzer, Poli Mara |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Casanova, Gislaine Krolow Spritzer, Poli Mara |
dc.subject.por.fl_str_mv |
Lipídeos Pós-menopausa Progesterona Estrogênios Terapia de reposição hormonal |
topic |
Lipídeos Pós-menopausa Progesterona Estrogênios Terapia de reposição hormonal Lipid profile Early postmenopause Micronized progesterone Non-oral estrogen Hormone therapy |
dc.subject.eng.fl_str_mv |
Lipid profile Early postmenopause Micronized progesterone Non-oral estrogen Hormone therapy |
description |
Background: Much attention has been drawn to the deleterious effects of adding progestins to estrogen as hormone therapy (HT) in postmenopausal women. Some widely prescribed progestins have been shown to partially oppose the beneficial effects of estrogens on surrogate markers of cardiovascular disease (CVD) risk. Progestins with higher androgenic activity may interfere with lipid profile and glucose tolerance, and could affect mechanisms of estrogen-induced C-reactive protein (CRP) stimulation. Recent data have shown that norpregnane derivatives, but not micronized progesterone, increase the risk of venous thromboembolism among transdermal estrogens users. The aim of the present study was to assess the effects of combining micronized progesterone with non-oral estrogen therapy on lipid profile and cardiovascular risk factors in a sample of early postmenopausal women. Methods: Clinical trial including 40 women receiving intranasal 17β estradiol 3 mg/day for two months and 46 women receiving percutaneous 17β estradiol gel 1.5 mg/day for three months (E2). Both groups received an additional 200 mg/day of micronized progesterone by vaginal route 14 days/month (E2+P). Outcome measures included body weight, waist circumference, body mass index (BMI), lipid profile and ultra-sensitive C-reactive protein (usCRP) at baseline and during the E2 or E2+P portions of treatment. Results: Mean age was 51±3 years. Mean time since menopause was 22.2±10 months. Most participants were overweight; HT did not change BMI. E2 and E2+P did not affect waist circumference and weight. Menopausal symptoms improved after HT. The effects of intranasal and percutaneous estradiol were similar, regardless of the addition of progesterone. Similarly, for the overall group of 86 women, micronized progesterone did not alter the response to E2. Blood pressure, glucose, insulin, HDL-c, triglycerides, and usCRP remained constant with or without micronized progesterone. Total cholesterol decreased after E2, and progesterone maintained this reduction. LDL-c levels were similar at baseline and with E2, and lower during E2+P in relation to baseline. Conclusions: Cyclic, short term exposure to vaginal micronized progesterone did not alter the metabolic and cardiovascular effects of non-oral E2 in early, apparently healthy, postmenopausal women. Trial registration: ClinicalTrials.gov NCT01432028. |
publishDate |
2012 |
dc.date.issued.fl_str_mv |
2012 |
dc.date.accessioned.fl_str_mv |
2015-02-11T02:18:07Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/109962 |
dc.identifier.issn.pt_BR.fl_str_mv |
1476-511X |
dc.identifier.nrb.pt_BR.fl_str_mv |
000867380 |
identifier_str_mv |
1476-511X 000867380 |
url |
http://hdl.handle.net/10183/109962 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Lipids in health and disease. London. Vol. 11 (2012), 7p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/109962/1/000867380.pdf http://www.lume.ufrgs.br/bitstream/10183/109962/2/000867380.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/109962/3/000867380.pdf.jpg |
bitstream.checksum.fl_str_mv |
8661a524680ced1e5b27ad02bc8a471a 7daa1b76766cb532f6c2b51fb18d7083 8c38cffd5aba14c9119f1082d9ca9f9c |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801224865475198976 |